ArticleThe World Allergy Organization journal2026
Clinical expressions, disease course, quality of life, and resilience in subgroups of patients with angioedema.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical expressions, disease course, quality of life, and resilience in subgroups of patients with angioedema.The World Allergy Organization journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Patients with angioedema caused by C1INH deficiency (HAE-C1INH) experience recurrent episodes of unpredictable swelling. Recently, new genetic variants have been identified, whereas patients with unknown causes and no identifiable genetic mutations constitute a distinct subgroup. As a lifelong condition, angioedema significantly impacts the patient's quality of life and ability to cope. With the emergence of new angioedema variants, comparing the characteristics and coping experiences across different designated subgroups presents an important unmet need. Materials and methods: A cross-sectional, prospective study was performed to analyze 3 angioedema subgroups: A: Hereditary Angioedema Types 1,2 (HAE-C1INH), B: Hereditary Angioedema with factor 12 mutation (HAE-FXII), and C: Angioedema with unknown cause (AE-UNK). Two validated questionnaires were used: The Evaluation of Prodromes and Attacks Questionnaire (HAE-EPA, part Q1) and the 10-item Connor-Davidson Resilience Scale (CD-RISC). Results: The study involved 111 patients with a mean age of 44.51 years. The mean age of onset was 16.1 years, and the mean age at diagnosis was 19.58 years. Subgroups A, B, and C consisted of 72 (64%), 16 (14%), and 23 (20%) patients, respectively. The mean age of onset was earlier in the A subgroup (10.31 years) than in the B (19.70 years) and C (30.34 years) subgroups (p < 0.001). Similarly, the mean age at diagnosis was earlier in the A subgroup (13.85 years) compared to the B (24.93 years) and C (34.73 years) subgroups (p < 0.001). Significant differences were found in the triggers of attacks, but not in the body location of the attacks or in the experience of pre-attack prodromes. Subgroup A reported the highest mean coping ability (7.88 ± 2.44) compared to those in Subgroup B (5.13 ± 3.07) and Subgroup C (5.48 ± 2.81) (F = 41.6, p < .001). The mean quality of life was significantly higher in Subgroup A (8.47 ± 2.06) than in Subgroup C (7.74 ± 1.76) (F = 13.0, p < .001). The mean total Connor-Davidson Resilience score was highest in Subgroup A (31.25 ± 4.86), followed by Subgroup B (30.87 ± 5.21), and lowest in Subgroup C (27.21 ± 6.43) (F = 5.19, p < 0.001). Conclusion: The designated subgroups differ in both clinical course and coping strategies. Recognizing the unique characteristics of each AE subgroup can improve the management and quality of life of patients with this lifelong and rare disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.